Re:Cognition Health opens first clinic in the USA
Clinic launch announced at the SelectUSA Summit 2018
The opening of the clinic comes in response to the success of the company’s UK clinical trial operations and high international demand for such medical facilities. Re:Cognition Health and the Fairfax County Economic Development Authority (FCEDA) made the announcement on 21st June, 2018 at the 2018 SelectUSA Summit. Organised by the U.S. Department of Commerce, the Summit promotes foreign direct investment in the United States.
Award-winning provider of clinical trials for Alzheimer’s disease
Re:Cognition Health is recognised for its outstanding contribution to patient recruitment across multiple clinical trial protocols. The company’s expansion into the USA will help change the future for those with memory loss and other symptoms of cognitive impairment.
Today, 5.7 million Americans are living with Alzheimer’s disease. According to the Alzheimer’s Association, this number is predicted to rise to nearly 14 million by 2050. Working in partnership with global pharmaceutical companies, many of whom have their HQs based in the USA, and collaborating with industry-leading experts, Re:Cognition Health is one of the most successful clinical groups in the world for enrolling individuals onto clinical studies for Alzheimer’s disease and dementia.
Alzheimer’s disease is the only leading cause of death that is still on the rise
The population of the American market provides a platform for major, continued business expansion and important medical research. The USA offers the landscape to conduct multiple clinical trials in an increasingly ageing demographic. Clinical trials help advance our knowledge of the disease and bring us ever-closer to finding new treatments. Results from clinical trials have been encouraging. New treatments are designed to slow down and/or halt the progression of the disease. Re:Cognition Health supports the development of Alzheimer’s drugs by effective patient recruitment and outstanding clinical services.
Dr Emer MacSweeney, CEO, comments: “We are excited to expand Re:Cognition Health’s centres into the USA, allowing for the opportunity for more people to gain access the most advanced treatments available, world-wide.”
Re:Cognition Health joins the Global Alzheimer’s Platform (GAP) Foundation
GAP is a patient-centric, non-profit organisation dedicated to speeding the delivery of innovative therapies to those afflicted with Alzheimer’s by reducing the time and cost of Alzheimer’s disease clinical trials. Re:Cognition Health is the only non US/Canadian member of the GAP network.
Dr. James Bicksel announced as Principal Investigator at Re:Cognition Health USA
Dr. Bicksel is a Neurologist and Medical Director of the Inova Memory Center at Inova Fairfax Hospital. Dr Bicksel is an ex-officio board member of the Alzheimer’s Association for the National Capital Area Chapter.
On the opening of the Fairfax clinic, Dr Bicksel comments: “Opening a new clinical for clinical studies for Alzheimer’s Disease is a very positive step for the future in fighting this disease. Our patients will have the opportunity to be involved in clinical trials of the next generation of emerging medications whilst receiving outstanding medical care by a team of cognitive experts. We are very much looking forward to making a difference to the lives of people in Virginia and Washington DC.”
About Fairfax, Virginia
The Washington D.C., area, which includes Fairfax, is the third-largest metropolitan area in the U.S. in healthcare spending. Per-person spending is 17 percent above the national average. Time Magazine described Fairfax as “One of the great economic success stories of our time.” In Fairfax, a cluster of life sciences companies drawn by region-wide workforce of 65,000 skilled life-sciences professionals, work in research and development, precision medicine, pharmaceuticals and bio-defense supported by a network of health-related IT companies specialising in clinical integration and data analytics.
Re:Cognition Health currently employs nine people in the USA and 65 in the UK. The company has ambitious growth plans and intends to open 15 additional clinics in the USA.